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Abstract
Background:  Matrix metalloproteinases (MMPs) are key regulatory molecules in the formation,
remodeling and degradation of all extracellular matrix (ECM) components in both physiological and
pathological processes in various tissues. The aim of this study was to examine the involvement of
gelatinase MMP family members, MMP-2 and MMP-9, in dystrophin-deficient skeletal muscle. Towards this
aim, we made use of the canine X-linked muscular dystrophy in Japan (CXMDJ) model, a suitable animal
model for Duchenne muscular dystrophy.
Methods: We used surgically biopsied tibialis cranialis muscles of  normal male dogs (n = 3) and CXMDJ
dogs (n = 3) at 4, 5 and 6 months of age. Muscle sections were analyzed by conventional morphological
methods and in situ zymography to identify the localization of MMP-2 and MMP-9. MMP-2 and MMP-9
activity was examined by gelatin zymography and the levels of the respective mRNAs in addition to those
of regulatory molecules, including MT1-MMP, TIMP-1, TIMP-2, and RECK, were analyzed by semi-
quantitative RT-PCR.
Results: In CXMDJ skeletal muscle, multiple foci of both degenerating and regenerating muscle fibers
were associated with gelatinolytic MMP activity derived from MMP-2 and/or MMP-9. In CXMDJ muscle,
MMP-9 immunoreactivity localized to degenerated fibers with inflammatory cells. Weak and disconnected
immunoreactivity of basal lamina components was seen in MMP-9-immunoreactive necrotic fibers of
CXMDJ muscle. Gelatinolytic MMP activity observed in the endomysium of groups of regenerating fibers
in CXMDJ did not co-localize with MMP-9 immunoreactivity, suggesting that it was due to the presence of
MMP-2. We observed increased activities of pro MMP-2, MMP-2 and pro MMP-9, and levels of the mRNAs
encoding MMP-2, MMP-9 and the regulatory molecules, MT1-MMP, TIMP-1, TIMP-2, and RECK in the
skeletal muscle of CXMDJ dogs compared to the levels observed in normal controls.
Conclusion: MMP-2 and MMP-9 are likely involved in the pathology of dystrophin-deficient skeletal
muscle. MMP-9 may be involved predominantly in the inflammatory process during muscle degeneration.
In contrast, MMP-2, which was activated in the endomysium of groups of regenerating fibers, may be
associated with ECM remodeling during muscle regeneration and fiber growth.
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Background
Duchenne muscular dystrophy (DMD) is the most com-
mon lethal X-linked recessive disease, presenting with
progressive muscular atrophy and weakness. DMD is
caused by mutations in the DMD gene that encodes the
cytoskeletal protein dystrophin. Dystrophin and the dys-
trophin-associated protein complex provide a crucial
structural link between the extracellular matrix (ECM)
and the intracellular actin cytoskeleton [1]. Dystrophin
deficiency affects the sarcolemma-ECM interaction, result-
ing in sarcolemmal instability [2,3]. Histopathological
hallmarks in DMD include degeneration, necrosis, and
insufficient regeneration of muscle fibers, suggesting that
constitutive ECM remodeling takes place in DMD skeletal
muscles. Although the cycles of degeneration and regener-
ation of muscle fibers continues throughout postnatal
development, regeneration gradually slows and the bal-
ance is eventually tipped in favor of degeneration in DMD
[4].
ECM is a three-dimensional network of macromolecules,
and transmits signals from cells to the ECM and vice versa,
mediating cell adhesion, migration, proliferation, differ-
entiation and survival [5]. Muscle fibers are embedded in
connective tissue organized into three interconnected
sheaths: (1) Epimysium is a collagenous tissue that sur-
rounds whole muscle; (2) Perimysium is smaller bundles
of collagen fibers extended inward from epimysium, sep-
arates muscle fibers into fascicles or bundles; (3) Endomy-
sium encloses the individual muscle fibers, including
basal lamina, capillaries, fine nerve branches, fibroblasts,
and macrophages [6]. The basal lamina, which consists of
ECM components such as type IV collagen, laminin, and
proteoglycans, maintains the physiological integrity of the
muscle fibers and has a role in muscle fiber repair after
injury or excessive exercise [7]. In the last decade, matrix
metalloproteinases (MMPs) have been shown to degrade
all ECM components [8]. MMPs, a group of zinc-depend-
ent endopeptidases, are thought to play a central role in
the modulation of ECM functions [9]. MMPs are com-
monly induced by cytokine signals as inactive zymogens
(pro-forms), that require processing of a prodomain by
other MMPs or serine proteinases to attain full activity.
Their activities are inhibited by endogenous MMP inhibi-
tors (tissue inhibitors of metalloproteinases; TIMPs-1, -2,
-3, and -4) [10,11]. Membranous type metalloproteinases
(MT-MMPs) have recently been discovered as a subgroup
of membrane-anchored metalloproteinases. Membra-
nous type metalloproteinase-1 (MT1-MMP) is associated
with pro matrix metalloproteinase type 2 (pro MMP-2)
and TIMP-2 to form a trimolecular complex, that activates
pro MMP-2. [12-16]. Reversion-inducing-cysteine-rich
protein with Kazal Motifs (RECK) is a new class of mem-
brane-anchored inhibitor of MMP-2, matrix metallopro-
teinase type 9 (MMP-9), and MT1-MMP [17]. RECK has
been described as a tumor and metastasis suppressor, as
well as an angiogenesis suppressor and regulator of ECM
integrity [18,19]. MMP activity contributes to a variety of
physiological processes, such as embryonic development,
organ morphogenesis, cell migration, apoptosis, angio-
genesis, cartilage remodeling, bone growth, and wound
healing [8,10,20]. On the other hand, loss of the exquisite
regulation of MMPs leads to extensive ECM degradation,
resulting in various diseases such as tumor progression or
metastasis, cerebrovascular diseases, cardiovascular dis-
eases, rheumatoid arthritis, and lung diseases. Therefore,
MMP inhibitors can be useful prospective agents for the
prevention and treatment of these diseases [21-27].
With respect to muscular disorders, particular attention
has been paid to a subgroup of MMPs termed 'gelatinases,'
comprising MMP-2 (also called gelatinase A, or 72-kDa
type IV collagenase) and MMP-9 (also called gelatinase B,
or 92-kDa type V collagenase). These enzymes contain
three repeats of a gelatin-binding type II fibronectin
domain inserted into their catalytic domain [28]. Besides
gelatin, they degrade various ECM components including
denatured type I, II, and III collagen, native IV and V col-
lagen, laminin, elastin, proteoglycan, and fibronectin
[28,29]. In some inflammatory myopathies, MMP-9 is
expressed primarily by invading T lymphocytes, and is
implicated in the pathogenesis [30-32]. MMP-2 is up-reg-
ulated in DMD skeletal muscle, and is expressed by mes-
enchymal fibroblastic cells [33]. Up-regulation of MMP-2
and MMP-9 has also been observed in skeletal muscle of
dystrophin-deficient mdx mice [34,35], an animal model
of DMD. Moreover, it has been reported that MMP-2 and
MMP-9 are able to process beta-dystroglycan and disrupt
the link between the ECM and the cell membrane via the
dystroglycan complex in the skeletal muscle from DMD
and sarcoglycanopathy patients [36-38].
We hypothesized that MMP-2 and/or MMP-9 might also
play an important role in the pathogenesis of muscular
dystrophies, involving ECM remodeling during the cycle
of muscle fiber degeneration and regeneration. We evalu-
ated the expression, activation, and immunolocalization
of MMP-2 and MMP-9, as well as of regulatory molecules
MT1-MMP, TIMP-1, TIMP-2 and RECK, in the dystrophin-
deficient skeletal muscle of the canine X-linked muscular
dystrophy in Japan (CXMDJ) model of DMD, which
shows more prominent skeletal muscle involvement than
mdx mice [39].
Methods
Animals
CXMDJ dogs were established by insemination of beagles
with the sperm of golden retriever muscular dystrophy
(GRMD) dogs [40]. CXMDJ dogs lack dystrophin in the
sarcolemma of skeletal muscles and exhibit typical dys-BMC Musculoskeletal Disorders 2007, 8:54 http://www.biomedcentral.com/1471-2474/8/54
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trophic phenotypes, as observed in DMD and GRMD
[39,41]. We studied three normal male dogs (Beagle) at 4,
5 and 6 months of age and three age-matched CXMDJ
dogs. Each of the CXMDJ dogs presented with typical clin-
ical signs of muscular dystrophy: progressive muscular
atrophy and weakness, and elevated serum creatine kinase
(CK) levels. The tibialis cranialis muscles of control and
CXMDJ dogs were obtained by surgical biopsy at the Gen-
eral Animal Research Facility of the National Institute of
Neuroscience at the National Center of Neurology and
Psychiatry (NCNP, Tokyo, Japan). The samples were rap-
idly frozen in isopentane cooled by liquid nitrogen. The
treating and care of the dogs, and all experimental proce-
dures, were approved by the Ethics Committee for the
Treatment of Laboratory Middle-Sized Animal of the
National Institute of Neuroscience, National Center of
Neurology and Psychiatry (NCNP) (Tokyo, Japan). All
experiments were performed with appropriate measures
taken for preventing unnecessary pain.
Film in situ zymography
To detect the localization of gelatinolytic MMP activity in
skeletal muscle tissues, we performed film in situ zymog-
raphy (FIZ) as previously described [42-48]. 6 μm-thick
cryosections from frozen samples were placed on a poly-
ethylene terephthalate base film coated with 7 μm thick-
ness cross-linked gelatin with (FIZ-GI, Wako Pure
Chemical, Osaka, Japan) or without (FIZ-GN, Wako Pure
Chemical) 1,10-phenanthroline (inhibitor of MMPs, but
not of other proteinases such as trypsin). The films with
sections were incubated in a moist chamber for 6 hours at
37°C. Then the films were stained with Biebrich Scarlet
for 4 min and rinsed for 10 min at room temperature. The
degraded gelatin was not stained with Biebrich Scarlet,
and areas of gelatinolytic activity were visualized as white
or weakly red areas on the red background. Gelatinolysis
observed on FIZ-GN films, but not on FIZ-GI films, indi-
cated the presence of MMP activity. Gelatinolysis seen on
both FIZ-GN and FIZ-GI films indicated the activity of
proteases other than MMPs (such as trypsin). The applica-
tion of gelatin as substrate for in situ zymography has the
advantage that MMP-2 and/or MMP-9 have a high affinity
for this substrate [49].
Histopathology and immunohistochemistry
Serial 8 μm-thick cryosections of frozen muscle were pre-
pared and stained with hematoxylin and eosin (HE). The
sections were blocked with 10% goat serum (Cedarlane
Laboratories, Burlington, Canada) in PBS for 15 min and
incubated at 4°C overnight with primary antibodies, fol-
lowed by secondary staining. Stained specimens were
mounted in Vectashield with DAPI (4', 6-diamidino-2-
phenylindole, dihydrochloride) (Vector Laboratories,
Burlingame, CA) for nuclear counterstaining and photo-
graphed using a fluorescence microscope BX51 (OLYM-
PUS, Tokyo, Japan) equipped with an air-cooled CCD
camera VB-7010 (KEYENCE, Oosaka, Japan) and VB-
Viewer software (KEYENCE). Primary antibodies were
used as follows: rabbit anti-MMP-2 antibody (AB809,
Chemicon International, Temecula, CA), rabbit anti-
MMP-9 antibody (AB19047, Chemicon International),
mouse anti-CD11b antibody (MCA1777S, Serotec,
Oxford, UK), mouse-anti myosin developmental type
heavy chain (NCL-MHCd, Novocastra, Newcastle Upon
Tyne, UK), mouse anti-laminin B2 antibody (MAB1920,
Chemicon International), rat anti-heparan sulfate prote-
oglycan, perlecan antibody (MAB1948, Chemicon Inter-
national), rabbit anti-TIMP-1 antibody (sc-5538, Santa
Cruz Biotechnology, Santa Cruz, CA), rabbit anti-TIMP-2
antibody (sc-5539, Santa Cruz Biotechnology), goat anti-
MT1-MMP antibody (sc-12367, Santa Cruz Biotechnol-
ogy), and goat anti-RECK antibody (sc-8689, Santa Cruz
Biotechnology). CD11b is a leukocyte-associated antigen
expressed on monocytes, macrophages, and granulocytes
[50]. Myosin developmental type heavy chain (MHCd) is
a myosin heavy chain isoform, present during muscle
fiber regeneration, in the embryonic and neonatal periods
[51].
Gelatin zymography
Frozen skeletal muscles were homogenized in an extrac-
tion buffer (62.5 mM Tris-HCl pH 6.8, 2% sodium
dodecyl sulfate (SDS) 10% glycerol) and total protein
content was assessed by the Bio-Rad DC Assay kit (Bio-
Rad Laboratories, Hercules, CA). 100 μg of each extract
dissolved in a loading buffer provided by the manufacture
were electrophoresed through a gelatin-containing SDS
polyacrylamide gel provided as part of the gelatin zymog-
raphy kit (Gelatin Zymography kit, Yagai, Tokyo, Japan).
The gel was washed with washing buffer and then incu-
bated for 36 hours at 37°C in reaction buffer, provided by
the manufacture. The gels were stained in Coomasie Bril-
liant Blue and destained with destain solution (Bio-Rad
Laboratories). Gelatinolytic activity was identified as clear
bands on a blue background. Gelatin zymography detects
the activity of both active and pro-form gelatinolytic
MMPs. This is because exposure to SDS during gel electro-
phoresis causes activation of the pro-form MMPs without
proteolytic cleavage of the prodomain [52]. Quantitative
results of the assays were obtained by densitometry using
ImageJ v1.34s (National Institutes of Health; NIH,
Bethesda, MD).
RNA isolation and reverse transcription
Total RNA was isolated from the skeletal muscles using
the RNeasy fibrous tissue mini kit (QIAGEN, Hilden, Ger-
many) and RNA quality was spectrophotometrically
assessed. Reverse transcription to cDNA was performed in
buffered solution containing dATP, dCTP, dGTP, dTTP,
FPLCpure murine reverse transcriptase, RNA guard (por-BMC Musculoskeletal Disorders 2007, 8:54 http://www.biomedcentral.com/1471-2474/8/54
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cine), RNase/DNase-free bovine serum albumin, and
NotI-d (T) 18 primer [5'-
d(AACTGGAAGAATTCGCGGCCGCAGGAAT18)-3']
according to the manufacturer's instructions, using the
Ready-To-Go T-Primed First Strand Reaction Kit (Pharma-
cia Biotech, Brussels, Belgium).
Semi-quantitative RT-PCR
The PCR amplifications were carried out in the presence of
1.5 mM MgCl2 by using standard PCR buffer, 0.2 mM
dNTPs, 0.4 mM of each forward and reverse primer, 1 μl
of RT products, and 0.1 units Taq DNA polymerase in a
total volume of 25 μl. We designed PCR primers based on
the previously published cDNAs of the canine gene
sequences for MMP-2, MMP-9, MT1-MMP, TIMP-1, TIMP-
2, and RECK (Table 1). 18S ribosomal RNA was used as an
internal control in the semi-quantitative RT-PCR experi-
ments. A 324 bp fragment of 18s was amplified using
QuantumRNA™ Classic II 18S Internal Standard
(Ambion, Austin, TX). 18S rRNA primers were mixed with
competimers at an optimized ratio of 5:5 so that the signal
for 18S rRNA was attenuated to the level of messages of
targets by modulating the efficiency of amplification of
the 18S PCR product. The PCR conditions were: initial
denaturation for 1 min at 94°C; followed by 30 cycles (for
MT1-MMP, TIMP-1, and TIMP-2), or 32 cycles (for MMP-
9 and RECK) of 94°C for 30 sec, 60°C for 30 sec and 72°C
for 30 sec; and a final extension of 10 min at 72°C. The
number of cycles was determined experimentally so that
semi-quantitative comparison could be made during the
exponential phase of the amplification process for each
target and 18S rRNA gene. The relative expression level of
each target gene was calculated by normalization against
the 18s rRNA level. The PCR products were electro-
phoresed through a 2.5% agarose gel stained with ethid-
ium bromide. The gel images were obtained using the
GENE FLASH syngene bio imaging (TopoGEN, Port
Orange, FL), and the densities of the products were quan-
tified using ImageJ v1.34s (NIH). All assays were con-
ducted in triplicate.
Statistical analysis
Quantitative data were compared in both groups by
Mann-Whitney's U test. The data are presented as mean ±
SEM. P < 0.05 was considered to indicate statistical signif-
icance.
Results
Histopathology and in situ zymography
CXMDJ muscles showed typical histopathological hall-
marks of degeneration and regeneration. Multiple foci of
both degenerating and regenerating muscle fibers were
observed simultaneously in the same section (Fig. 1C).
We examined the localization of gelatinolytic activity in
the skeletal muscle of control and CXMDJ dogs. In con-
trols, low gelatinolytic activity was detected in the
endomysium (Fig. 1A,B). In contrast, strong activity was
detected in the endomysial space with infiltrating inflam-
matory cells in CXMDJ muscles (Fig. 1D,E). Moreover, the
endomysium of groups of regenerating fibers showed
prominent gelatinolytic activity in CXMDJ muscles (Fig.
1F,G).
We next examined the fibers characterized by prominent
gelatinolytic activity using immunohistochemistry.
Strong gelatinase activity was detected in the endomysium
not only of fibers with infiltration of CD11b positive cells
(Fig. 2A,B,C), but also of MHCd-positive, small caliber,
centronuclear fibers (Fig. 2E,F,G), which represent degen-
erating and regenerating fibers, respectively. Gelatinolytic
activity was attenuated by the MMP inhibitor, 1,10-phen-
anthrolone (Fig. 2D,H), indicating that it was specifically
derived from MMPs, and not from other proteases.
Immunohistochemistry of MMP-9
In CXMDJ muscle, MMP-9 immunoreactivity was detected
in the necrotic fibers with inflammatory cell invasion and
their endomysial space. MMP-9 immunoreactivity was co-
localized with that of CD11b (Fig. 3G–J). Some MMP-9-
positive fibers had degenerated and showed a weak and
discontinuous immunoreactivity pattern of basal lamina
components, perlecan (Fig. 3O–R) and laminin B2 (Fig.
3S–V). On the other hand, regenerating fibers (MHCd-
positive fibers) in CXMDJ muscle did not show MMP-9
immunoreactivity (Fig. 3K–N). Control muscle did not
show a significant immunoreactivity for MMP-9, CD11b
and MHCd (Fig. 3B,C and 3D, respectively), and revealed
a normal immunoreactivity of perlecan and laminin B2
(Fig. 3E and 3F, respectively). Each immunohistochemis-
try of MMP-2, MT1-MMP, TIMP-1, TIMP-2, or RECK failed
because of poor immunoreactivity of each antibody to the
canine isoforms.
Gelatin zymography
We next evaluated the activity of each of the gelatinolytic
enzymes (MMP-2, pro MMP-2 and pro MMP-9) in the
muscle of normal and CXMDJ dogs by gelatin zymogra-
phy analysis. This analysis detected gelatinolytic enzyme
activity associated with proteins of molecular weights cor-
responding to 74 kDa, 64 kDa and 92 kDa, which indicate
the presence of pro MMP-2, and the active forms of MMP-
2 and pro MMP-9, respectively. The activities of the three
enzymes, particularly pro MMP-9, were increased in
CXMDJ muscle compared to control samples. MMP-9 was
only detected as the pro-form (Fig. 4A). A semi-quantita-
tive analysis showed a significant difference in each MMP
activity between CXMDJ and normal dog muscle (Fig. 4B).BMC Musculoskeletal Disorders 2007, 8:54 http://www.biomedcentral.com/1471-2474/8/54
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Table 1: Primer sets used for PCR
Target gene (GenBank accession No.) Primer set (Location of primer sequence)
MMP-2 Forward 5'-TGCAAGGCAGTGGTCATAGCT-3' (1724–1744)
(XM 535300) Reverse 5'-AGCCAGTCGGATTTGATGCT-3' (1829–1810)
MMP-9 Forward 5'-CCCTGCCACTTCCCCTTCACC-3' (707–727)
(AF 001003219) Reverse 5'-GAGCGGCCCTCGAAGGTGAAC-3' (895–915)
MT1-MMP Forward 5'-AGGAGACAAGCACTGGGTGTT-3' (38–58)
(AF 097638) Reverse 5'-AGGGATTCCTTCCCAGACCTT-3' (249–269)
TIMP-1 Forward 5'-CCGACTTAAACCGGCGTTAT-3' (201–220)
(NM 001003182) Reverse 5'-GATCAACACCTGCAGTTTCG-3' (401–420)
TIMP-2 Forward 5'-CAAAGCGGTCAGTGTGAAGG-3' (1–20)
(AF 095638) Reverse 5'-CTTTGTGACTTCATCGTGCC-3' (236–255)
RECK Forward 5'-TGCCCCGAAACAATGGTTGA-3' (246–265)
(NM 001002985) Reverse 5'-TCTCGGCAGTTTGTGTGATGG-3' (494–514)
Film in situ zymography (FIZ-GN) of skeletal muscle in CXMDJ dogs Figure 1
Film in situ zymography (FIZ-GN) of skeletal muscle in CXMDJ dogs. Hematoxylin and eosin (H&E) staining (A, C, D, 
and F) and film in situ zymography (FIZ-GN) (B, E, and G) of the tibialis cranialis muscle in a normal dog (A, B) and a CXMDJ 
dog (C-G). D and E (magnified views of C-a): a representative area of massive necrotic fibers with inflammatory infiltrate. F and 
G (magnified views of C-b): a representative area of a group of regenerating fibers. Gelatinolytic activities were visualized as 
white or weakly red areas on the red background. Bars, 100 μm.BMC Musculoskeletal Disorders 2007, 8:54 http://www.biomedcentral.com/1471-2474/8/54
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Semi-quantitative RT-PCR
We next analyzed each gene expression of the gelatinolytic
enzymes or the associated regulatory molecules in control
and CXMDJ dog muscle. A semi-quantitative analysis of
the mRNA level encoding MMP-2, MMP-9, MT1-MMP,
TIMP-1, TIMP-2, and RECK revealed that they were signif-
icantly increased in CXMDJ muscle compared to the levels
in control muscle (Fig. 5).
Discussion
Our data suggest that ECM remodeling mediated by
MMP-2 and MMP-9 is a key process in skeletal muscle
fiber degeneration and regeneration in CXMDJ dogs. An
FIZ assay revealed multiple foci of both degenerating and
regenerating muscle fibers associated with gelatinolytic
activity that was attenuated by exposure of the tissue to an
MMP inhibitor, 1,10-phenanthrolone, indicating the
presence of the activity of the gelatinolytic subgroup
MMPs, MMP-2 and MMP-9. We also observed increased
MMP-2 and MMP-9 activity and expression using gelatin
zymography and by measuring the corresponding
mRNAs, respectively. In addition, we observed increased
expression of the regulatory molecules, TIMP-1, TIMP-2,
RECK, and MT1-MMP. Overall proteolytic activity is not
easily predicted by RT-PCR findings on MMPs and their
regulators, but we performed FIZ to know total gelatinase
activities in situ. Our results showed that two proteases,
MMP-2 and/or MMP-9 were highly activated in certain
areas, although the data was not quantitative.
We showed that MMP-9 was localized to the endomysial
space of inflammation in CXMDJ muscle. MMP-9 seems
to be derived from infiltrating granulocytes, monocytes or
macrophages, since MMP-9 and CD11b immunoreactiv-
ity appear to co-localize. Degenerating fibers associated
with MMP-9 immunoreactivity exhibited weak and dis-
connected expression of basal lamina components, lam-
inin B2 and perlecan. These results suggest that MMP-9
may promote the degradation of the basal lamina in
necrotic fibers in CXMDJ muscle, followed by inflamma-
tory cell invasion. In cardiotoxin-injected mice, MMP-9
was induced within 24 h of injection into skeletal muscle
Immunohistochemical analysis of CD11b or MHCd expression, and film in situ zymography in the presence and absence of an  MMP inhibitor (FIZ-PT) in the skeletal muscle of CXMDJ dogs Figure 2
Immunohistochemical analysis of CD11b or MHCd expression, and film in situ zymography in the presence and 
absence of an MMP inhibitor (FIZ-PT) in the skeletal muscle of CXMDJ dogs. A-D: serial sections of CXMDJ muscle 
characterized by extensive necrosis and an invading inflammatory infiltrate; E-H: serial sections of groups of regenerating fibers 
in CXMDJ muscle. A and B: H&E staining; B and F: immunohistochemical analysis of CD11b; C and G: FIZ-GN; D and H: FIZ in 
the presence of an MMP inhibitor (1,10-phenanthrolone) (FIZ-PT). Gelatinolytic activity co-localized with CD11b and MHCd, 
immunoreactivity and was attenuated by adding 1,10-phenanthrolone to the FIZ assay system. Bars, 50 μm.BMC Musculoskeletal Disorders 2007, 8:54 http://www.biomedcentral.com/1471-2474/8/54
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and was associated with inflammatory cell invasion, and
MMP-9 mRNA was localized to invading polymorphonu-
clear cells and macrophages [34]. In human inflammatory
myopathies, it has been reported that MMP-9 is produced
primarily by invading T lymphocytes [30-32]. It is con-
ceivable that MMP-9 may also contribute to elimination
of necrotic fibers, so as to make room for muscle regener-
ation. MMP-9 is reported to be associated with muscle sat-
ellite cells; an adult muscle precursor and candidate
muscle stem cell, and cultured human muscle satellite
cells treated with phorbol ester [53]. MMP-9 mRNA was
expressed in putative activated satellite cells in injured
mouse muscle [34]. Taken together, these data suggest
that MMP-9 might be associated not only with ECM deg-
radation during inflammation, but also during the initia-
tion of muscle regeneration. In our experiments, we
detected only the latent form of MMP-9 (pro MMP-9) in
the gelatin zymography. Regarding MMP-9, it has been
reported that MMP-9 is not always detected in many tis-
sues in vivo, although pro MMP-9 is converted to MMP-9
by various protease such as MMP-1, MMP-2, MMP-3 or
plasminogen activator in vitro [54]. In addition, MMP-9
activation locally occurs in a pericellular environment by
inflammatory response, leaving much of the secreted
MMP in its pro-form [55].
Our data indicated that MMP-2 might be activated in the
endomysium of regenerating fibers in CXMDJ muscle. The
Co-immunolocalization of MMP-9, Perlecan, and laminin B2 in the skeletal muscle of CXMDJ dogs Figure 3
Co-immunolocalization of MMP-9, Perlecan, and laminin B2 in the skeletal muscle of CXMDJ dogs. H&E staining 
(A, G, K, O and S). Immunohistochemical analysis of MMP-9 (red), with nuclear counterstain using DAPI (blue) (B, H, L, P and 
T), CD11b (green, C and I), MHCd (green, D and M), Perlecan (green, E and Q), laminin B2 (green, F and U). Merged images of 
MMP-9 immunoreactivity with that of CD11b (J), MHCd (N), Perlecan (R) and laminin B2 (V) in normal control (A-F) and in a 
CXMDJ muscle (G-V). MMP-9 was detected in necrotic fibers associated with invading inflammatory cells and co-localized with 
CD11b (G-J). The endomysium of surrounding MHCd-positive regenerating fibers showed no MMP-9 immunoreactivity (K-M). 
A fraction of the MMP-9-positive fibers had degenerated and showed a weak and discontinuous pattern of immunostaining of 
both perlecan (O-R) and laminin B2 (S-V). Bars, 25 μm.BMC Musculoskeletal Disorders 2007, 8:54 http://www.biomedcentral.com/1471-2474/8/54
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endomysium of regenerating fibers were associated with
gelatinolytic MMP activity, but were not associated with
MMP-9 immunoreactivity. These results suggest that
MMP-2, but not MMP-9, is activated in the vicinity of
regenerating fibers. In a previous report, MMP-2 tran-
scripts were predominantly found in the areas of fiber
degeneration and ECM regeneration, and were localized
to mesenchymal fibroblasts in DMD skeletal muscle [33].
During muscle degeneration and regeneration induced by
cardiotoxin injection, MMP-2 activity seems to be
increased concomitantly with the transition from the
regeneration phases characterized by the appearance of
young myotubes to maturation of the myotubes into
multinucleated myofibers [34,56]. We therefore, assume
that MMP-2 may take part in ECM remodeling occurring
in the endomysium of regenerating fibers, as they grow
into mature fibers. Additionally, there are some reports
indicating that MMP-2 is involved in earlier phases of
muscle regeneration. In the mouse myoblastic C2C12 cell
line, MMP-2 and MT1-MMP promote myoblast fusion
[57], and MMP-2 could degrade the basal lamina compo-
nents during myoblast fusion [40].
TIMPs, endogenous tissue inhibitors of MMPs, have been
considered to be involved in the activities of MMPs. The
expression of TIMPs has been explored in some diseased
skeletal muscle, but their results were not conclusive. One
report mentioned that expression of TIMP-1 and TIMP-2
mRNA levels were not different between inflammatory
myopathies/inclusion body myositis and muscular dys-
trophy [32]. While, it has been also reported that both
TIMP-1 and TIMP-2 mRNA levels in DMD muscle were
increased than those in normal or other pathological con-
trols, resulting in the promotion of muscle fibrosis [33].
Therefore, it is valuable to compare expression of TIMPs
in dystrophin-deficiency and those in experimental mod-
els for muscle degeneration-regeneration. In our study, we
presented up-regulation of TIMPs in the same skeletal
muscle from CXMDJ at 4 to 6 months of age, where both
necrosis and regeneration was active and existed at the
same time. In injured mouse skeletal muscle by cardio-
toxin injection, the increase of TIMP-1 mRNA levels was
noticed a little later than the peak of MMP-9 mRNA,
whereas TIMP-2 mRNA levels were found corresponding
to the increase in MMP-2 mRNA (Fukushima et al.,
unpublished observations). We, therefore, suppose that
MMPs and TIMPs upregulation may depend on the stage
of muscle pathology; muscle necrosis or muscle regenera-
tion, although cardiotoxin injection into canine skeletal
muscle would allow us to directly compare muscle regen-
eration process and pathology of muscular dystrophy.
Conclusion
Based on our study, MMP-9 may be predominantly
involved in the inflammatory process during muscle
degeneration, while MMP-2 may be associated with ECM
remodeling during muscle regeneration and fiber growth.
To further elucidate the specific functions of each MMP
and TIMP, canine muscle injury model by injection of a
mytotoxic agent would be largely informative and there-
fore indispensable.
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